Is It A Rash Or Photosensitivity? FDA May Have To Distinguish Them In Simeprevir Label
Executive Summary
Antiviral Drugs Advisory Committee members debated whether both adverse reactions should be included in the simeprevir label’s “Warnings and Precautions” section and whether photosensitivity should automatically lead to stopping treatment.
You may also be interested in...
Janssen’s Simeprevir May Require Hep C Subpopulation Screening
FDA advisory committee briefing documents recommend patients be screened for the Q80K polymorphism because of lower efficacy in those patients, an issue not seen with Incivek or Victrelis.
Incivek Black Box Creates Fallout Risk For Vertex, FDA On Rash-related Fatalities
For Vertex, the key question is how much is physician and patient concern about the adverse events is already reflected in the softening sales of the hepatitis C drug; for FDA, the question is how effective will label-based risk management be.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.